230 related articles for article (PubMed ID: 26265695)
1. Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.
Sperlazza J; Rahmani M; Beckta J; Aust M; Hawkins E; Wang SZ; Zu Zhu S; Podder S; Dumur C; Archer K; Grant S; Ginder GD
Blood; 2015 Sep; 126(12):1462-72. PubMed ID: 26265695
[TBL] [Abstract][Full Text] [Related]
2. Acetyltransferase p300 collaborates with chromodomain helicase DNA-binding protein 4 (CHD4) to facilitate DNA double-strand break repair.
Qi W; Chen H; Xiao T; Wang R; Li T; Han L; Zeng X
Mutagenesis; 2016 Mar; 31(2):193-203. PubMed ID: 26546801
[TBL] [Abstract][Full Text] [Related]
3. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
[TBL] [Abstract][Full Text] [Related]
4. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
Xie C; Drenberg C; Edwards H; Caldwell JT; Chen W; Inaba H; Xu X; Buck SA; Taub JW; Baker SD; Ge Y
PLoS One; 2013; 8(11):e79106. PubMed ID: 24244429
[TBL] [Abstract][Full Text] [Related]
5. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW
J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049
[TBL] [Abstract][Full Text] [Related]
6. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
7. The chromatin-remodeling factor
Heshmati Y; Türköz G; Harisankar A; Kharazi S; Boström J; Dolatabadi EK; Krstic A; Chang D; Månsson R; Altun M; Qian H; Walfridsson J
Haematologica; 2018 Jul; 103(7):1169-1181. PubMed ID: 29599201
[TBL] [Abstract][Full Text] [Related]
8. The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage.
Larsen DH; Poinsignon C; Gudjonsson T; Dinant C; Payne MR; Hari FJ; Rendtlew Danielsen JM; Menard P; Sand JC; Stucki M; Lukas C; Bartek J; Andersen JS; Lukas J
J Cell Biol; 2010 Sep; 190(5):731-40. PubMed ID: 20805324
[TBL] [Abstract][Full Text] [Related]
9. The Chromatin Remodeler CHD4 Sustains Ewing Sarcoma Cell Survival by Controlling Global Chromatin Architecture.
Graca Marques J; Pavlovic B; Ngo QA; Pedot G; Roemmele M; Volken L; Kisele S; Perbet R; Wachtel M; Schäfer BW
Cancer Res; 2024 Jan; 84(2):241-257. PubMed ID: 37963210
[TBL] [Abstract][Full Text] [Related]
10. Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.
Nio K; Yamashita T; Okada H; Kondo M; Hayashi T; Hara Y; Nomura Y; Zeng SS; Yoshida M; Hayashi T; Sunagozaka H; Oishi N; Honda M; Kaneko S
J Hepatol; 2015 Nov; 63(5):1164-72. PubMed ID: 26095183
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies.
Gâtel P; Brockly F; Reynes C; Pastore M; Hicheri Y; Cartron G; Piechaczyk M; Bossis G
Life Sci Alliance; 2020 Jun; 3(6):. PubMed ID: 32303586
[TBL] [Abstract][Full Text] [Related]
12. CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes.
Xia L; Huang W; Bellani M; Seidman MM; Wu K; Fan D; Nie Y; Cai Y; Zhang YW; Yu LR; Li H; Zahnow CA; Xie W; Chiu Yen RW; Rassool FV; Baylin SB
Cancer Cell; 2017 May; 31(5):653-668.e7. PubMed ID: 28486105
[TBL] [Abstract][Full Text] [Related]
13. Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4.
Polo SE; Kaidi A; Baskcomb L; Galanty Y; Jackson SP
EMBO J; 2010 Sep; 29(18):3130-9. PubMed ID: 20693977
[TBL] [Abstract][Full Text] [Related]
14. SIRT6 coordinates with CHD4 to promote chromatin relaxation and DNA repair.
Hou T; Cao Z; Zhang J; Tang M; Tian Y; Li Y; Lu X; Chen Y; Wang H; Wei FZ; Wang L; Yang Y; Zhao Y; Wang Z; Wang H; Zhu WG
Nucleic Acids Res; 2020 Apr; 48(6):2982-3000. PubMed ID: 31970415
[TBL] [Abstract][Full Text] [Related]
15. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer.
Hou MF; Luo CW; Chang TM; Hung WC; Chen TY; Tsai YL; Chai CY; Pan MR
Exp Cell Res; 2017 Oct; 359(2):458-465. PubMed ID: 28842166
[TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
Qiu L; Zhou G; Cao S
Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
[TBL] [Abstract][Full Text] [Related]
17. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
[TBL] [Abstract][Full Text] [Related]
18. CHD4 Is a Peripheral Component of the Nucleosome Remodeling and Deacetylase Complex.
Low JK; Webb SR; Silva AP; Saathoff H; Ryan DP; Torrado M; Brofelth M; Parker BL; Shepherd NE; Mackay JP
J Biol Chem; 2016 Jul; 291(30):15853-66. PubMed ID: 27235397
[TBL] [Abstract][Full Text] [Related]
19. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
[TBL] [Abstract][Full Text] [Related]
20. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
